Gene expression and risk of leukemic transformation in myelodysplasia

Yusuke Shiozawa, Luca Malcovati, Anna Gallì, Andrea Pellagatti, Mohsen Karimi, Aiko Sato-Otsubo, Yusuke Sato, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hideki Makishima, Jacqueline Boultwood, Eva Hellström-Lindberg, Satoru Miyano, Mario Cazzola, Seishi Ogawa

Research output: Contribution to journalArticle

Abstract

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic disorders with a highly variable prognosis. To identify a gene expression–based classification of myelodysplasia with biological and clinical relevance, we performed a comprehensive transcriptomic analysis of myeloid neoplasms with dysplasia using transcriptome sequencing. Unsupervised clustering of gene expression data of bone marrow CD341 cells from 100 patients identified 2 subgroups. The first subtype was characterized by increased expression of genes related to erythroid/megakaryocytic (EMK) lineages, whereas the second subtype showed upregulation of genes related to immature progenitor (IMP) cells. Compared with the first so-called EMK subtype, the IMP subtype showed upregulation of many signaling pathways and downregulation of several pathways related to metabolism and DNA repair. The IMP subgroup was associated with a significantly shorter survival in both univariate (hazard ratio [HR], 5.0; 95% confidence interval [CI], 1.8-14; P 5 .002) and multivariate analysis (HR, 4.9; 95% CI, 1.3-19; P 5 .02). Leukemic transformation was limited to the IMP subgroup. The prognostic significance of our classification was validated in an independent cohort of 183 patients. We also constructed a model to predict the subgroups using gene expression profiles of unfractionated bone marrow mononuclear cells (BMMNCs). The model successfully predicted clinical outcomes in a test set of 114 patients with BMMNC samples. The addition of our classification to the clinical model improved prediction of patient outcomes. These results indicated biological and clinical relevance of our gene expression–based classification, which will improve risk prediction and treatment stratification of MDS.

Original languageEnglish
Pages (from-to)2642-2653
Number of pages12
JournalBlood
Volume130
Issue number24
DOIs
Publication statusPublished - Dec 14 2017
Externally publishedYes

Fingerprint

Gene expression
Genes
Bone Marrow Cells
Gene Expression
Bone
Myelodysplastic Syndromes
Transcriptome
Hazards
Up-Regulation
Confidence Intervals
Metabolism
DNA Repair
Cluster Analysis
Repair
Stem Cells
Down-Regulation
Multivariate Analysis
Survival
DNA
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Shiozawa, Y., Malcovati, L., Gallì, A., Pellagatti, A., Karimi, M., Sato-Otsubo, A., ... Ogawa, S. (2017). Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 130(24), 2642-2653. https://doi.org/10.1182/blood-2017-05-783050

Gene expression and risk of leukemic transformation in myelodysplasia. / Shiozawa, Yusuke; Malcovati, Luca; Gallì, Anna; Pellagatti, Andrea; Karimi, Mohsen; Sato-Otsubo, Aiko; Sato, Yusuke; Suzuki, Hiromichi; Yoshizato, Tetsuichi; Yoshida, Kenichi; Shiraishi, Yuichi; Chiba, Kenichi; Makishima, Hideki; Boultwood, Jacqueline; Hellström-Lindberg, Eva; Miyano, Satoru; Cazzola, Mario; Ogawa, Seishi.

In: Blood, Vol. 130, No. 24, 14.12.2017, p. 2642-2653.

Research output: Contribution to journalArticle

Shiozawa, Y, Malcovati, L, Gallì, A, Pellagatti, A, Karimi, M, Sato-Otsubo, A, Sato, Y, Suzuki, H, Yoshizato, T, Yoshida, K, Shiraishi, Y, Chiba, K, Makishima, H, Boultwood, J, Hellström-Lindberg, E, Miyano, S, Cazzola, M & Ogawa, S 2017, 'Gene expression and risk of leukemic transformation in myelodysplasia', Blood, vol. 130, no. 24, pp. 2642-2653. https://doi.org/10.1182/blood-2017-05-783050
Shiozawa Y, Malcovati L, Gallì A, Pellagatti A, Karimi M, Sato-Otsubo A et al. Gene expression and risk of leukemic transformation in myelodysplasia. Blood. 2017 Dec 14;130(24):2642-2653. https://doi.org/10.1182/blood-2017-05-783050
Shiozawa, Yusuke ; Malcovati, Luca ; Gallì, Anna ; Pellagatti, Andrea ; Karimi, Mohsen ; Sato-Otsubo, Aiko ; Sato, Yusuke ; Suzuki, Hiromichi ; Yoshizato, Tetsuichi ; Yoshida, Kenichi ; Shiraishi, Yuichi ; Chiba, Kenichi ; Makishima, Hideki ; Boultwood, Jacqueline ; Hellström-Lindberg, Eva ; Miyano, Satoru ; Cazzola, Mario ; Ogawa, Seishi. / Gene expression and risk of leukemic transformation in myelodysplasia. In: Blood. 2017 ; Vol. 130, No. 24. pp. 2642-2653.
@article{60b6c3d11db64876a40ac50f78b0434a,
title = "Gene expression and risk of leukemic transformation in myelodysplasia",
abstract = "Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic disorders with a highly variable prognosis. To identify a gene expression–based classification of myelodysplasia with biological and clinical relevance, we performed a comprehensive transcriptomic analysis of myeloid neoplasms with dysplasia using transcriptome sequencing. Unsupervised clustering of gene expression data of bone marrow CD341 cells from 100 patients identified 2 subgroups. The first subtype was characterized by increased expression of genes related to erythroid/megakaryocytic (EMK) lineages, whereas the second subtype showed upregulation of genes related to immature progenitor (IMP) cells. Compared with the first so-called EMK subtype, the IMP subtype showed upregulation of many signaling pathways and downregulation of several pathways related to metabolism and DNA repair. The IMP subgroup was associated with a significantly shorter survival in both univariate (hazard ratio [HR], 5.0; 95{\%} confidence interval [CI], 1.8-14; P 5 .002) and multivariate analysis (HR, 4.9; 95{\%} CI, 1.3-19; P 5 .02). Leukemic transformation was limited to the IMP subgroup. The prognostic significance of our classification was validated in an independent cohort of 183 patients. We also constructed a model to predict the subgroups using gene expression profiles of unfractionated bone marrow mononuclear cells (BMMNCs). The model successfully predicted clinical outcomes in a test set of 114 patients with BMMNC samples. The addition of our classification to the clinical model improved prediction of patient outcomes. These results indicated biological and clinical relevance of our gene expression–based classification, which will improve risk prediction and treatment stratification of MDS.",
author = "Yusuke Shiozawa and Luca Malcovati and Anna Gall{\`i} and Andrea Pellagatti and Mohsen Karimi and Aiko Sato-Otsubo and Yusuke Sato and Hiromichi Suzuki and Tetsuichi Yoshizato and Kenichi Yoshida and Yuichi Shiraishi and Kenichi Chiba and Hideki Makishima and Jacqueline Boultwood and Eva Hellstr{\"o}m-Lindberg and Satoru Miyano and Mario Cazzola and Seishi Ogawa",
year = "2017",
month = "12",
day = "14",
doi = "10.1182/blood-2017-05-783050",
language = "English",
volume = "130",
pages = "2642--2653",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Gene expression and risk of leukemic transformation in myelodysplasia

AU - Shiozawa, Yusuke

AU - Malcovati, Luca

AU - Gallì, Anna

AU - Pellagatti, Andrea

AU - Karimi, Mohsen

AU - Sato-Otsubo, Aiko

AU - Sato, Yusuke

AU - Suzuki, Hiromichi

AU - Yoshizato, Tetsuichi

AU - Yoshida, Kenichi

AU - Shiraishi, Yuichi

AU - Chiba, Kenichi

AU - Makishima, Hideki

AU - Boultwood, Jacqueline

AU - Hellström-Lindberg, Eva

AU - Miyano, Satoru

AU - Cazzola, Mario

AU - Ogawa, Seishi

PY - 2017/12/14

Y1 - 2017/12/14

N2 - Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic disorders with a highly variable prognosis. To identify a gene expression–based classification of myelodysplasia with biological and clinical relevance, we performed a comprehensive transcriptomic analysis of myeloid neoplasms with dysplasia using transcriptome sequencing. Unsupervised clustering of gene expression data of bone marrow CD341 cells from 100 patients identified 2 subgroups. The first subtype was characterized by increased expression of genes related to erythroid/megakaryocytic (EMK) lineages, whereas the second subtype showed upregulation of genes related to immature progenitor (IMP) cells. Compared with the first so-called EMK subtype, the IMP subtype showed upregulation of many signaling pathways and downregulation of several pathways related to metabolism and DNA repair. The IMP subgroup was associated with a significantly shorter survival in both univariate (hazard ratio [HR], 5.0; 95% confidence interval [CI], 1.8-14; P 5 .002) and multivariate analysis (HR, 4.9; 95% CI, 1.3-19; P 5 .02). Leukemic transformation was limited to the IMP subgroup. The prognostic significance of our classification was validated in an independent cohort of 183 patients. We also constructed a model to predict the subgroups using gene expression profiles of unfractionated bone marrow mononuclear cells (BMMNCs). The model successfully predicted clinical outcomes in a test set of 114 patients with BMMNC samples. The addition of our classification to the clinical model improved prediction of patient outcomes. These results indicated biological and clinical relevance of our gene expression–based classification, which will improve risk prediction and treatment stratification of MDS.

AB - Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic disorders with a highly variable prognosis. To identify a gene expression–based classification of myelodysplasia with biological and clinical relevance, we performed a comprehensive transcriptomic analysis of myeloid neoplasms with dysplasia using transcriptome sequencing. Unsupervised clustering of gene expression data of bone marrow CD341 cells from 100 patients identified 2 subgroups. The first subtype was characterized by increased expression of genes related to erythroid/megakaryocytic (EMK) lineages, whereas the second subtype showed upregulation of genes related to immature progenitor (IMP) cells. Compared with the first so-called EMK subtype, the IMP subtype showed upregulation of many signaling pathways and downregulation of several pathways related to metabolism and DNA repair. The IMP subgroup was associated with a significantly shorter survival in both univariate (hazard ratio [HR], 5.0; 95% confidence interval [CI], 1.8-14; P 5 .002) and multivariate analysis (HR, 4.9; 95% CI, 1.3-19; P 5 .02). Leukemic transformation was limited to the IMP subgroup. The prognostic significance of our classification was validated in an independent cohort of 183 patients. We also constructed a model to predict the subgroups using gene expression profiles of unfractionated bone marrow mononuclear cells (BMMNCs). The model successfully predicted clinical outcomes in a test set of 114 patients with BMMNC samples. The addition of our classification to the clinical model improved prediction of patient outcomes. These results indicated biological and clinical relevance of our gene expression–based classification, which will improve risk prediction and treatment stratification of MDS.

UR - http://www.scopus.com/inward/record.url?scp=85038406176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038406176&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-05-783050

DO - 10.1182/blood-2017-05-783050

M3 - Article

C2 - 29097382

AN - SCOPUS:85038406176

VL - 130

SP - 2642

EP - 2653

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -